Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population

Authors: Marta Podralska, Iwona Ziółkowska-Suchanek, Magdalena Żurawek, Agnieszka Dzikiewicz-Krawczyk, Ryszard Słomski, Jerzy Nowak, Agnieszka Stembalska, Karolina Pesz, Maria Mosor

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

DNA damage repair is a complex process, which can trigger the development of cancer if disturbed. In this study, we hypothesize a role of variants in the ATM, H2AFX and MRE11 genes in determining breast cancer (BC) susceptibility.

Methods

We examined the whole sequence of the ATM kinase domain and estimated the frequency of founder mutations in the ATM gene (c.5932G > T, c.6095G > A, and c.7630-2A > C) and single nucleotide polymorphisms (SNPs) in H2AFX (rs643788, rs8551, rs7759, and rs2509049) and MRE11 (rs1061956 and rs2155209) among 315 breast cancer patients and 515 controls. The analysis was performed using high-resolution melting for new variants and the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method for recurrent ATM mutations. H2AFX and MRE11 polymorphisms were analyzed using TaqMan assays. The cumulative genetic risk scores (CGRS) were calculated using unweighted and weighted approaches.

Results

We identified four mutations (c.6067G > A, c.8314G > A, c.8187A > T, and c.6095G > A) in the ATM gene in three BC cases and two control subjects. We observed a statistically significant association of H2AFX variants with BC. Risk alleles (the G of rs7759 and the T of rs8551 and rs2509049) were observed more frequently in BC cases compared to the control group, with P values, odds ratios (OR) and 95% confidence intervals (CIs) of 0.0018, 1.47 (1.19 to 1.82); 0.018, 1.33 (1.09 to 1.64); and 0.024, 1.3 (1.06 to 1.59), respectively. Haplotype-based tests identified a significant association of the H2AFX CACT haplotype with BC (P <  0.0001, OR = 27.29, 95% CI 3.56 to 209.5). The risk of BC increased with the growing number of risk alleles. The OR (95% CI) for carriers of ≥ four risk alleles was 1.71 (1.11 to 2.62) for the CGRS.

Conclusions

This study confirms that H2AFX variants are associated with an increased risk of BC. The above-reported sequence variants of MRE11 genes may not constitute a risk factor of breast cancer in the Polish population. The contribution of mutations detected in the ATM gene to the development of breast cancer needs further detailed study.
Literature
1.
Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene. 2007;26(56):7749–58.CrossRefPubMed
2.
3.
Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, et al. A high proportion of founder BRCA1 mutations in polish breast cancer families. Int J Cancer. 2004;110(5):683–6.CrossRefPubMed
4.
Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzanska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, et al. Founder mutations in the BRCA1 gene in polish families with breast-ovarian cancer. Am J Hum Genet. 2000;66(6):1963–8.CrossRefPubMedPubMedCentral
5.
Bak A, Janiszewska H, Junkiert-Czarnecka A, Heise M, Pilarska-Deltow M, Laskowski R, Pasinska M, Haus O. A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the north - Central Poland. Hered Cancer Clin Pract. 2014;12(1):10.CrossRefPubMedPubMedCentral
6.
Cybulski C, Wokolorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojc B, Deebniak T, Gorski B, Blecharz P, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29(28):3747–52.CrossRefPubMed
7.
Cybulski C, Kluzniak W, Huzarski T, Wokolorczyk D, Kashyap A, Jakubowska A, Szwiec M, Byrski T, Debniak T, Gorski B, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015;16(6):638–44.CrossRefPubMed
8.
Cybulski C, Carrot-Zhang J, Kluzniak W, Rivera B, Kashyap A, Wokolorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet. 2015;47(6):643–6.CrossRefPubMed
9.
Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, Keller JJ, Westerman AM, Scott RJ, Lim W, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15.CrossRefPubMed
10.
Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, et al. TP53 germline mutation testing in 180 families suspected of li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010;47(6):421–8.CrossRefPubMed
11.
Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014;343(6178):1466–70.CrossRefPubMedPubMedCentral
12.
Byrnes GB, Southey MC, Hopper JL. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res. 2008;10(3):208.CrossRefPubMedPubMedCentral
13.
Zurawek M, Fichna M, Fichna P, Skowronska B, Dzikiewicz-Krawczyk A, Januszkiewicz D, Nowak J. Cumulative effect of IFIH1 variants and increased gene expression associated with type 1 diabetes. Diabetes Res Clin Pract. 2015;107(2):259–66.CrossRefPubMed
14.
Ziolkowska-Suchanek I, Mosor M, Wierzbicka M, Rydzanicz M, Baranowska M, Nowak J. The MRN protein complex genes: MRE11 and RAD50 and susceptibility to head and neck cancers. Mol Cancer. 2013;12(1):113.CrossRefPubMedPubMedCentral
15.
Kaluzna EM, Rembowska J, Ziolkowska-Suchanek I, Swiatek-Koscielna B, Gabryel P, Dyszkiewicz W, Nowak JS. Heterozygous p.I171V mutation of the NBN gene as a risk factor for lung cancer development. Oncol Lett. 2015;10(5):3300–4.CrossRefPubMedPubMedCentral
16.
Mosor M, Ziolkowska I, Pernak-Schwarz M, Januszkiewicz-Lewandowska D, Nowak J. Association of the heterozygous germline I171V mutation of the NBS1 gene with childhood acute lymphoblastic leukemia. Leukemia. 2006;20(8):1454–6.CrossRefPubMed
17.
Nowak J, Mosor M, Ziolkowska I, Wierzbicka M, Pernak-Schwarz M, Przyborska M, Roznowski K, Plawski A, Slomski R, Januszkiewicz D. Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours. Eur J Cancer. 2008;44(4):627–30.CrossRefPubMed
18.
Ziolkowska I, Mosor M, Nowak J. Regional distribution of heterozygous 657del5 mutation carriers of the NBS1 gene in Wielkopolska province (Poland). J Appl Genet. 2006;47(3):269–72.CrossRefPubMed
19.
Mosor M, Ziolkowska-Suchanek I, Roznowski K, Baranowska M, Januszkiewicz-Lewandowska D, Nowak J. RAD50 gene mutations are not likely a risk factor for breast cancer in Poland. Breast Cancer Res Treat. 2010;123(2):607–9.CrossRefPubMed
20.
Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991;325(26):1831–6.CrossRefPubMed
21.
Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97(11):813–22.CrossRefPubMed
22.
Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38(8):873–5.CrossRefPubMed
23.
Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB. Van 't veer LJ: the spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2008;107(2):243–8.CrossRefPubMed
24.
Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly MJ, Buys SM, Southey MC, et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 2011;13(4):R73.CrossRefPubMedPubMedCentral
25.
Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE, Langholz B, Thomas DC, Bernstein L, Lynch CF, Olsen JH, et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst. 2010;102(7):475–83.CrossRefPubMedPubMedCentral
26.
Gonzalez-Hormazabal P, Bravo T, Blanco R, Valenzuela CY, Gomez F, Waugh E, Peralta O, Ortuzar W, Reyes JM, Jara L. Association of common ATM variants with familial breast cancer in a south American population. BMC Cancer. 2008;8:117.CrossRefPubMedPubMedCentral
27.
Podralska MJ, Stembalska A, Slezak R, Lewandowicz-Uszynska A, Pietrucha B, Koltan S, Wigowska-Sowinska J, Pilch J, Mosor M, Ziolkowska-Suchanek I, et al. Ten new ATM alterations in polish patients with ataxia-telangiectasia. Mol Genet Genomic Med. 2014;2(6):504–11.CrossRefPubMedPubMedCentral
28.
Mitui M, Bernatowska E, Pietrucha B, Piotrowska-Jastrzebska J, Eng L, Nahas S, Teraoka S, Sholty G, Purayidom A, Concannon P, et al. ATM gene founder haplotypes and associated mutations in polish families with ataxia-telangiectasia. Ann Hum Genet. 2005;69(Pt 6):657–64.CrossRefPubMed
29.
Bogdanova N, Cybulski C, Bermisheva M, Datsyuk I, Yamini P, Hillemanns P, Antonenkova NN, Khusnutdinova E, Lubinski J, Dork T. A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer. Breast Cancer Res Treat. 2009;118(1):207–11.CrossRefPubMed
30.
Cybulski C, Lubinski J, Wokolorczyk D, Kuzniak W, Kashyap A, Sopik V, Huzarski T, Gronwald J, Byrski T, Szwiec M, et al. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clin Genet. 2015;88(4):366–70.CrossRefPubMed
31.
Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A. 2002;99(2):925–30.CrossRefPubMedPubMedCentral
32.
Mangone FR, Miracca EC, Feilotter HE, Mulligan LM, Nagai MA. ATM gene mutations in sporadic breast cancer patients from Brazil. Spring. 2015;4:23.CrossRef
33.
Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kozarewa I, Fenwick K, Assiotis I, Barrowdale D, et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer. 2014;110(6):1663–72.CrossRefPubMedPubMedCentral
34.
Roznowski K, Januszkiewicz-Lewandowska D, Mosor M, Pernak M, Litwiniuk M, Nowak J. I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer. Breast Cancer Res Treat. 2008;110(2):343–8.CrossRefPubMed
35.
Ziolkowska I, Mosor M, Wierzbicka M, Rydzanicz M, Pernak-Schwarz M, Nowak J. Increased risk of larynx cancer in heterozygous carriers of the I171V mutation of the NBS1 gene. Cancer Sci. 2007;98(11):1701–5.CrossRefPubMed
36.
Nowak J, Mosor M, Nowicka K, Rembowska J, Januszkiewicz D. Is the NBN gene mutation I171V a potential risk factor for malignant solid tumors in children? J Pediatr Hematol Oncol. 2011;33(6):e248–9.CrossRefPubMed
37.
Cybulski C, Gorski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojc B, Jakubowska A, Matyjasik J, Zlowocka E, Sikorski A, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res. 2004;64(4):1215–9.CrossRefPubMed
38.
Dzikiewicz-Krawczyk A, Mosor M, Januszkiewicz D, Nowak J. Impact of heterozygous c.657-661del, p.I171V and p.R215W mutations in NBN on nibrin functions. Mutagenesis. 2012;27(3):337–43.CrossRefPubMed
39.
Fan W, Zhou K, Zhao Y, Wu W, Chen H, Jin L, Chen G, Shi J, Wei Q, Zhang T, et al. Possible association between genetic variants in the H2AFX promoter region and risk of adult glioma in a Chinese Han population. J Neuro-Oncol. 2011;105(2):211–8.CrossRef
40.
Srivastava N, Gochhait S, de Boer P, Bamezai RN. Role of H2AX in DNA damage response and human cancers. Mutat Res. 2009;681(2–3):180–8.CrossRefPubMed
41.
Novik KL, Spinelli JJ, Macarthur AC, Shumansky K, Sipahimalani P, Leach S, Lai A, Connors JM, Gascoyne RD, Gallagher RP, et al. Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomark Prev. 2007;16(6):1098–106.CrossRef
42.
Choudhury A, Elliott F, Iles MM, Churchman M, Bristow RG, Bishop DT, Kiltie AE. Analysis of variants in DNA damage signalling genes in bladder cancer. BMC Med Genet. 2008;9:69.CrossRefPubMedPubMedCentral
43.
Bretherick KL, Leach S, Brooks-Wilson AR. Functional characterization of genetic polymorphisms in the H2AFX distal promoter. Mutat Res. 2014;766-767:37–43.CrossRefPubMed
44.
Lu J, Wei Q, Bondy ML, Brewster AM, Bevers TB, Yu TK, Buchholz TA, Meric-Bernstam F, Hunt KK, Singletary SE, et al. Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged <or=55 years. Breast Cancer Res Treat. 2008;110(2):357–66.CrossRefPubMed
45.
Teo MT, Dyrskjot L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, et al. Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. Ann Oncol. 2014;25(4):877–83.CrossRefPubMedPubMedCentral
Metadata
Title
Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population
Authors
Marta Podralska
Iwona Ziółkowska-Suchanek
Magdalena Żurawek
Agnieszka Dzikiewicz-Krawczyk
Ryszard Słomski
Jerzy Nowak
Agnieszka Stembalska
Karolina Pesz
Maria Mosor
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4360-3

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Study protocol

Study protocol for a controlled trial of an eHealth system utilising patient reported outcome measures for personalised treatment and care: PROMPT-Care 2.0

Research article

Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma

Research article

Untargeted lipidomic features associated with colorectal cancer in a prospective cohort

Research article

Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis

Research article

Comparative study of dual energy CT iodine imaging and standardized concentrations before and after chemoradiotherapy for esophageal cancer

Research article

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits